Alle Storys
Folgen
Keine Story von Sanacorp Pharmaholding AG mehr verpassen.

Sanacorp Pharmaholding AG

EANS-Adhoc: Sanacorp Pharmaholding AG
Sanacorp disposes of Anzag investment

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
18.10.2010
The pharmaceutical wholesale company Sanacorp Pharmahandel GmbH 
("Sanacorp GmbH"), which is indirectly owned by Sanacorp 
Pharmaholding Aktiengesellschaft via its 50 percent interest in the 
Italian holding company Sanastera S.p.A., Bologna, signed an 
agreement on October 18th., 2010 stipulating the sale of 
approximately 24.99% in the capital stock of Andreae-Noris Zahn AG, 
Frankfurt (WKN 504700/ISIN DE0005047005). Acquirer is an investment 
company of the Alliance Boots Group. The implementation of the share 
purchase agreement is subject to the responsible cartel authorities´ 
approval.
The purchase price agreed per share is EUR 26.00. Sanacorp GmbH will 
thus receive cash flows of more than EUR 69 million expected to be 
used for the settlement of liabilities.
Sanacorp Pharmaholding AG
The Management Board
end of announcement                               euro adhoc

Further inquiry note:

Dr. Thomas Strieder
Phone: +49(89) 8581 494
E-Mail: t.strieder@sanacorp.de

Branche: Wholesale
ISIN: DE0007163131
WKN: 716313
Index: CDAX, Classic All Share
Börsen: Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / regulated dealing
Frankfurt / regulated dealing/general standard

Weitere Storys: Sanacorp Pharmaholding AG
Weitere Storys: Sanacorp Pharmaholding AG